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 Lymphocytic choriomeningitis, is a rodent-borne viral infectious disease 
caused by Lymphocytic choriomeningitis virus (LCMV), a member of the 
family Arenaviridae, that was initially isolated in 1933. Acquired postnatal 
infection ranges from asymptomatic to a brief, nonspecific flu-like illness to 
critical self-resolving neurological disease, predominantly consisting of aseptic 
meningitis or meningoencephalitis. This study was undertaken to design an 
epitope-based peptide vaccine against Lymphocytic choriomeningitis virus 
using a computational biology approach. Twenty four sequences of LCMV 
were retrieved from UniProt database and analyzed with various in silico tools. 
VaxiJen was used to identify immunogenic peptides and T-cell epitopes were 
analysed using NetCTL server to identify T-cell epitopes. Out of 15 
immunogenic peptides analysed using NetCTL server, a conservancy of 
64.28% amongst all epitopes was observed. The peptide sequence 
VVQNLDQLY, a non-allergen, was found to be a potent T-cell epitope that 
interacted with 28 human leukocyte antigens (HLAs) and its interaction with 
HLA-A*02:06 was studied using protein-protein docking analysis. The HLA 
allele and the epitope VVQNLDQLY were found to effectively interact with 
each other and this epitope may be used as a vaccine against LCMV. Thus 
immunoinformatics based approaches can be used to predict vaccine candidates 
against pathogens in a timely manner and usher us into an era of T-cell based 
novel vaccinomics approach. 
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1. INTRODUCTION 
A novel approach integrating immunoinformatics and immunogenomics for the development of 
vaccines is known as vaccinomics [1]. The present conventional approach for vaccine development relies on 
antigen expression, in sufficient amount, from in vitro culture models; however, many antigens, while expressed 
sufficiently, may not be good candidates for vaccine. With these conventional approaches, it has not been 
possible to control different types of outbreaks of viral pathogens, such as recent avian, swine flu and influenza 
strains, due to time-consuming development process for vaccines. Hence, rapid in silico informatics-based 
approach has gained much popularity with the recent advancement in the sequencing of many pathogen 
genomes and protein sequence databases [2]. The “vaccinomics” approach has already proven to be essential for 
combating diseases such as multiple sclerosis [3], malaria [4], and some tumors [5]. However, these methods of 
vaccine development usually work through the identification of human leukocyte antigens (HLA) ligands and T-
cell epitopes [6], which specify the selection of the potent vaccine candidates associated with the transporter of 
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antigen presentation (TAP) molecules [7-10]. The overall idea behind vaccinomics is to identify genetic and 
other mechanisms and pathways that determine immune responses, and thereby provide new candidate vaccine 
approaches [11]. 
Lymphocytic choriomeningitis virus (LCMV) is an enveloped single-stranded RNA virus of the 
Arenaviridae family. It is an important cause of neurologic disease in humans and covers a large geographic 
range. Wild mice are the natural host and principal reservoir of LCMV, but the virus can also be found in pet 
hamsters, golden hamsters, and guinea pigs. Humans acquire LCMV disease when they come into contact with 
the secretions of infected mice. When the virus is acquired postnatally by children or adults, the clinical 
manifestations are usually those of aseptic meningitis. Most people who acquire LCMV infection during 
childhood or adulthood are moderately symptomatic for several weeks, but have a full recovery. A much more 
severe disease ensues when the infection occurs prenatally. LCMV can infect the fetal brain and retina, where it 
leads to substantial injury and permanent dysfunction. The possibility of LCMV infection should be considered 
in all babies with evidence of congenital infection, especially those with prominent neurologic signs, such as 
microencephaly, periventricular calcifications, and hydrocephalus [12].  
At present, vaccines are mostly based on B cell immunity. But recently, vaccine based on T-cell 
epitope has been encouraged as the host can generate a strong immune response by CD8+ T-cell against the 
infected cell. With time, due to antigenic drift, any foreign particle can escape the antibody memory response; 
however, the T-cell immune response often provides long-lasting immunity [13]. 
The aim of the present study is to predict a T-cell epitope having therapeutic potential as an effective 
vaccine that could be suitable to trigger a significant immune response against Lymphocytic choriomeningitis 
virus. 
 
 
2. RESEARCH METHOD  
2.1 Protein sequence retrieval & Evolutionary analysis 
Twenty four protein sequences of LCMV were retrieved from the UniProtKB database [14] in the 
FASTA format. To construct a phylogenetic tree for the analysis of evolutionary divergence in the various 
protein sequences of LCMV, Clustal Omega [15], a multiple sequence alignment tool was used. 
 
2.2 Immunological analysis using In silico tools 
 
2.2.1 Antigenic protein identification  
Antigenic protein identification was done using VaxiJen v2.0 server that classifies peptides as antigenic 
or non-antigenic [16]. 
 
2.2.2 T-cell epitope identification 
The NetCTL 1.2 server was used for the identification of the T-cell epitope. The epitope prediction was 
restricted to 12 MHC-I supertypes and the method integrated peptide major histocompatibility complex class I 
(MHC-I) binding; proteasomal C terminal cleavage, and TAP transport efficiency [17]. 
 
2.2.3 Identification of MHC-I allele – T-cell epitope interaction & Epitope conservancy analysis 
Tools from the Immune Epitope Database (IEDB) [18] that is based on stabilized matrix base method 
(SMM) [19] was used to calculate the half-maximal inhibitory concentration (IC50) values of peptide binding to 
MHC-I molecules.  The analysis of the epitope conservancy was done using web-based tool from IEDB analysis 
resource [20]. 
 
2.2.4 Allergenicity assessment 
Allergenecity i.e whether the epitope is allergen or non-allergen was predicted by AllerTOP 1.0 and 
AlgPred. AllerTOP is the first alignment-free server for in silico prediction of allergens based on the main 
physicochemical properties of proteins [21]. Allergenecity was also predicted using another tool i.e. AlgPred 
that allows prediction of allergens based on similarity of known epitope with any region of protein [22]. 
 
2.3 Prediction and validation 
The structure of the epitope was predicted using I-TASSER server [23]. This server modelled five 3D 
structures of the epitope, and the structure with highest C-mean score was selected for further studies. The  3D 
structure of the protein was predicted using I-TASSER was validated by Verify3D [24] that  determines the 
compatibility of an atomic model (3D) with its own amino acid sequence (1D) by assigning a structural class 
based on its location and environment (alpha, beta, loop, polar, nonpolar etc) and comparing the results to good 
structures. 
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2.4 Docking Studies 
To analyse the interaction between HLA molecule and the epitope, a protein-protein docking study was 
performed using PatchDock [25] and ZDOCK [26] servers. The structure of HLA was obtained from PDB. The 
docked models obtained from PatchDock and ZDOCK were superimposed using online tool, SuperPose [27] to 
compare the docking and interactions between T-cell epitope and HLA. 
 
 
3. RESULTS AND ANALYSIS  
Twenty four protein sequences of LCMV were retrieved from UniProtKb and multiple sequence 
alignment was performed amongst various strains followed by construction of phylogenetic tree using Clustal 
Omega (Figure 1).  
 
 
Figure 1: Phylogenetic Tree of various strains of LCMV obtained using Clustal Omega. 
 
All 24 peptide sequences were then investigated using VaxiJen server out of which 15 peptides were 
found to be antigenic. These 15 sequences were further investigated for the prediction of T-cell epitopes using 
NetCTL server. 
Top five best epitopes having highest combinatorial score were selected (Table 1) and further 
investigated for HLA-allele interactions and epitope conservancy using IEDB conservancy analysis tool. 
Amongst these T-cell epitopes, a 9mer epitope, VVQNLDQLY was found to interact with most number of HLA 
alleles i.e. 28 with two other 9-mer epitopes QMHGVAITY and HRHDGIMLY having similar epitope 
conservancy of 66.28%. Therefore based on both conservancy and maximum number of interactions of epitope 
with MHC-I alleles, the epitope VVQNLDQLY was selected.  
 
Table 1: Epitopes selected on the basis of overall score predicted using NetCTL sever. 
Epitopes Overall score Epitopes Overall score Epitopes Overall score 
RTWENHCRY 3.4600 AALKNLCFY 3.1390 LIKEFSELY 3.0350 
RTWENHCTY 3.4200 ALVKRMKLY 3.1360 WTPGLSGIY 3.0156 
VVQNLDQLY 3.2470 FYMDKLNKY 3.1290 QTFVSQPGY 3.0050 
HRHDGIMLY 3.2240 SSVFSIEVY 3.1060 ALTDLGLLY 3.0030 
QMHGVAITY 3.2210 MDSDTPGFY 3.0180 SLVRCHDHY 2.9360 
  
Allergenecity was predicted by AllerTOP and AlgPred server and the epitope, VVQNLDQLY was 
found to be a non-allergen. The tertiary structure of the epitope, VVQNLDQLY was predicted using I-
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TASSER. This was validated using Verify3D and the residue numbers 20-400, 500-780 and 820-880 were 
found to be well predicted as they had a  score close to +1 while only few residues (400-500 and 830-870) were 
seen to have not been predicted reliably. Therefore it may be concluded that the overall quality of the structure 
of the epitope, VVQNLDQLY predicted using I-TASSER was good. 
The HLA-A*02:06 which interacted with our proposed epitope was selected for docking as its structure 
was available in PDB (PDB ID: 3OXR). This structure of HLA A*02:06 had a bound HBV Core 18-27 which 
was removed before performing docking studies. Protein-protein docking analysis of allele HLA-A*02:06 and 
the epitope VVQNLDQLY was performed using PatchDock and ZDOCK (Figure 2).  
 
  
 
Figure 2: Docking of epitope, VVQNLDQLY and HLA-A*02:06  obtained from (A) PatchDock and visualised 
using Pymol (Yellow color represents the interacting allele and Green color represents the epitope, 
VVQNLDQLY) (B) zDOCK (Grey color represents the epitope, VVQNLDQLY and yelow color represents the 
interacting allele) 
 
On superimposing the docked structures of HLA allele and epitope using SuperPose tool, the RMSD 
was zero thereby validating the interaction and results obtained from PatchDock & zDock. Therefore it can be 
concluded that the allele HLA-A*02:06  and epitope VVQNLDQLY effectively interact with each other and the 
epitope may be used as a vaccine against LCMV. 
Vaccinomics helps in the development of a new vaccine in a timely fashion which is very crucial in 
recent times due to ever rising global burden of disease. The advancement of in-silico tools and sequence-based 
technology has resulted in availability of genomic and proteomic data of different viruses which can be used to 
design peptide vaccines based on neutralizing epitopes. Knowledge about the peptide‟s epitopes has a key role 
for manufacturing epitope-based vaccines, which when injected into the recipient, can induce an immune 
response. 
Therefore in the present study we have been able to design a T-cell epitope based vaccine for 
Lymphocytic choriomeningitis virus using immunoinformatics based approach. This approach may be used to 
predict vaccine candidates for other pathogens in a timely manner.  
 
 
4. CONCLUSION 
The immunoinformatics based approach to design vaccines can help achieve effective, cost- efficient 
development of vaccines or vaccine components against pathogens such as LCMV with the validation of the 
prediction expected to be done by the wet lab researcher. 
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